{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T07:45:05Z","timestamp":1784706305853,"version":"3.55.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Leading Project for Leading Geese Plan of Zhejiang Provincial, China","award":["Grant No. 2025C02062"],"award-info":[{"award-number":["Grant No. 2025C02062"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biol Direct"],"DOI":"10.1186\/s13062-026-00824-1","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T10:25:10Z","timestamp":1778149510000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A pyroptosis-related molecular signature stratifies prognosis and highlights GSDMB-mediated malignancy in intrahepatic cholangiocarcinoma"],"prefix":"10.1186","volume":"21","author":[{"given":"Binhan","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongji","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyang","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kainan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunkun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Hua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,7]]},"reference":[{"key":"824_CR1","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41575-025-01153-w","volume":"23","author":"JM Banales","year":"2026","unstructured":"Banales JM, et al. Cholangiocarcinoma 2026: status quo, unmet needs and priorities. Nat Rev Gastroenterol Hepatol. 2026;23:65\u201396. https:\/\/doi.org\/10.1038\/s41575-025-01153-w.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"824_CR2","doi-asserted-by":"publisher","first-page":"127","DOI":"10.3350\/cmh.2025.0889","volume":"32","author":"CX Liu","year":"2026","unstructured":"Liu CX, Wong CC. Stratifying cholangiocarcinoma: tumor microenvironment, molecular drivers, and novel immunotherapeutic approaches. Clin Mol Hepatol. 2026;32:127\u201355. https:\/\/doi.org\/10.3350\/cmh.2025.0889.","journal-title":"Clin Mol Hepatol"},{"key":"824_CR3","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1016\/j.suc.2024.04.003","volume":"104","author":"JM Harrison","year":"2024","unstructured":"Harrison JM, Visser BC, Cholangiocarcinoma. Surg Clin North Am. 2024;104:1281\u201393. https:\/\/doi.org\/10.1016\/j.suc.2024.04.003.","journal-title":"Surg Clin North Am"},{"key":"824_CR4","doi-asserted-by":"publisher","first-page":"346","DOI":"10.3322\/caac.21779","volume":"73","author":"SM Ruff","year":"2023","unstructured":"Ruff SM, Diaz DA, Pitter KL, Hartwell BC, Pawlik TM. Multidisciplinary management in the treatment of intrahepatic cholangiocarcinoma. CA Cancer J Clin. 2023;73:346\u201352. https:\/\/doi.org\/10.3322\/caac.21779.","journal-title":"CA Cancer J Clin"},{"key":"824_CR5","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/s41575-022-00739-y","volume":"20","author":"DF Calvisi","year":"2023","unstructured":"Calvisi DF, et al. Criteria for preclinical models of cholangiocarcinoma: scientific and medical relevance. Nat Rev Gastroenterol Hepatol. 2023;20:462\u201380. https:\/\/doi.org\/10.1038\/s41575-022-00739-y.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"824_CR6","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","volume":"17","author":"JM Banales","year":"2020","unstructured":"Banales JM, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17:557\u201388. https:\/\/doi.org\/10.1038\/s41575-020-0310-z.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"824_CR7","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1055\/s-0040-1719188","volume":"37","author":"P Entezari","year":"2020","unstructured":"Entezari P, Riaz A. Intrahepatic Cholangiocarcinoma. Semin Intervent Radiol. 2020;37:475\u201383. https:\/\/doi.org\/10.1055\/s-0040-1719188.","journal-title":"Semin Intervent Radiol"},{"key":"824_CR8","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s40001-022-00741-9","volume":"27","author":"Y Song","year":"2022","unstructured":"Song Y, Cai M, Li Y, Liu S. The focus clinical research in intrahepatic cholangiocarcinoma. Eur J Med Res. 2022;27:116. https:\/\/doi.org\/10.1186\/s40001-022-00741-9.","journal-title":"Eur J Med Res"},{"key":"824_CR9","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1159\/000531458","volume":"13","author":"C Yoo","year":"2024","unstructured":"Yoo C, Hyung J, Chan SL. Recent Advances in Systemic Therapy for Advanced Intrahepatic Cholangiocarcinoma. Liver Cancer. 2024;13:119\u201335. https:\/\/doi.org\/10.1159\/000531458.","journal-title":"Liver Cancer"},{"key":"824_CR10","doi-asserted-by":"publisher","first-page":"198","DOI":"10.3322\/caac.21759","volume":"73","author":"D Moris","year":"2023","unstructured":"Moris D, et al. Advances in the treatment of intrahepatic cholangiocarcinoma: An overview of the current and future therapeutic landscape for clinicians. CA Cancer J Clin. 2023;73:198\u2013222. https:\/\/doi.org\/10.3322\/caac.21759.","journal-title":"CA Cancer J Clin"},{"key":"824_CR11","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s12916-024-03381-4","volume":"22","author":"M Zhu","year":"2024","unstructured":"Zhu M, et al. Anti-PD-1 antibody in combination with radiotherapy as first-line therapy for unresectable intrahepatic cholangiocarcinoma. BMC Med. 2024;22:165. https:\/\/doi.org\/10.1186\/s12916-024-03381-4.","journal-title":"BMC Med"},{"key":"824_CR12","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s41419-023-06406-7","volume":"15","author":"Y Feng","year":"2024","unstructured":"Feng Y, et al. The heterogeneity of signaling pathways and drug responses in intrahepatic cholangiocarcinoma with distinct genetic mutations. Cell Death Dis. 2024;15:34. https:\/\/doi.org\/10.1038\/s41419-023-06406-7.","journal-title":"Cell Death Dis"},{"key":"824_CR13","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1158\/1078-0432.Ccr-21-1157","volume":"28","author":"S Chen","year":"2022","unstructured":"Chen S, et al. Multiomic Analysis Reveals Comprehensive Tumor Heterogeneity and Distinct Immune Subtypes in Multifocal Intrahepatic Cholangiocarcinoma. Clin Cancer Res. 2022;28:1896\u2013910. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-21-1157.","journal-title":"Clin Cancer Res"},{"key":"824_CR14","doi-asserted-by":"publisher","unstructured":"Dong L, et al. Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma. Cancer Cell. 2022;40:70\u201387 e15. https:\/\/doi.org\/10.1016\/j.ccell.2021.12.006.","DOI":"10.1016\/j.ccell.2021.12.006"},{"key":"824_CR15","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/s41392-021-00507-5","volume":"6","author":"P Yu","year":"2021","unstructured":"Yu P, et al. Pyroptosis: mechanisms and diseases. Signal Transduct Target Ther. 2021;6:128. https:\/\/doi.org\/10.1038\/s41392-021-00507-5.","journal-title":"Signal Transduct Target Ther"},{"key":"824_CR16","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41580-025-00837-0","volume":"26","author":"Y Bai","year":"2025","unstructured":"Bai Y, Pan Y, Liu X. Mechanistic insights into gasdermin-mediated pyroptosis. Nat Rev Mol Cell Biol. 2025;26:501\u201321. https:\/\/doi.org\/10.1038\/s41580-025-00837-0.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"824_CR17","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1038\/s41556-024-01474-z","volume":"26","author":"KW Chen","year":"2024","unstructured":"Chen KW, Broz P. Gasdermins as evolutionarily conserved executors of inflammation and cell death. Nat Cell Biol. 2024;26:1394\u2013406. https:\/\/doi.org\/10.1038\/s41556-024-01474-z.","journal-title":"Nat Cell Biol"},{"key":"824_CR18","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/s41577-019-0228-2","volume":"20","author":"P Broz","year":"2020","unstructured":"Broz P, Pelegrin P, Shao F. The gasdermins, a protein family executing cell death and inflammation. Nat Rev Immunol. 2020;20:143\u201357. https:\/\/doi.org\/10.1038\/s41577-019-0228-2.","journal-title":"Nat Rev Immunol"},{"key":"824_CR19","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1186\/s12943-025-02506-4","volume":"24","author":"A Alishvandi","year":"2025","unstructured":"Alishvandi A, Aram C, Shahrivar FF, Kesharwani P, Sahebkar A. Pyroptosis in cancer therapy: a double-edged sword for immune activation and tumor progression. Mol Cancer. 2025;24:297. https:\/\/doi.org\/10.1186\/s12943-025-02506-4.","journal-title":"Mol Cancer"},{"key":"824_CR20","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s13045-025-01763-6","volume":"18","author":"W Seo","year":"2025","unstructured":"Seo W, et al. Inflammasomes and pyroptosis in cancer: mechanisms and therapeutic advances. J Hematol Oncol. 2025;18:113. https:\/\/doi.org\/10.1186\/s13045-025-01763-6.","journal-title":"J Hematol Oncol"},{"key":"824_CR21","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s40164-023-00464-5","volume":"12","author":"M Li","year":"2023","unstructured":"Li M, et al. The role of pyroptosis and gasdermin family in tumor progression and immune microenvironment. Exp Hematol Oncol. 2023;12:103. https:\/\/doi.org\/10.1186\/s40164-023-00464-5.","journal-title":"Exp Hematol Oncol"},{"key":"824_CR22","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.7150\/ijbs.54442","volume":"17","author":"H He","year":"2021","unstructured":"He H, et al. USP24-GSDMB complex promotes bladder cancer proliferation via activation of the STAT3 pathway. Int J Biol Sci. 2021;17:2417\u201329. https:\/\/doi.org\/10.7150\/ijbs.54442.","journal-title":"Int J Biol Sci"},{"key":"824_CR23","doi-asserted-by":"publisher","first-page":"e2411375","DOI":"10.1002\/advs.202411375","volume":"12","author":"H Gao","year":"2025","unstructured":"Gao H, et al. Caspase-6\/Gasdermin C-Mediated Tumor Cell Pyroptosis Promotes Colorectal Cancer Progression Through CXCL2-Dependent Recruitment of Myeloid-Derived Suppressor Cells. Adv Sci (Weinh). 2025;12:e2411375. https:\/\/doi.org\/10.1002\/advs.202411375.","journal-title":"Adv Sci (Weinh)"},{"key":"824_CR24","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1186\/s12964-024-01890-6","volume":"22","author":"H Gao","year":"2024","unstructured":"Gao H, et al. Gasdermin D promotes development of intestinal tumors through regulating IL-1beta release and gut microbiota composition. Cell Commun Signal. 2024;22:511. https:\/\/doi.org\/10.1186\/s12964-024-01890-6.","journal-title":"Cell Commun Signal"},{"key":"824_CR25","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41586-022-05400-x","volume":"612","author":"R Xue","year":"2022","unstructured":"Xue R, et al. Liver tumour immune microenvironment subtypes and neutrophil heterogeneity. Nature. 2022;612:141\u20137. https:\/\/doi.org\/10.1038\/s41586-022-05400-x.","journal-title":"Nature"},{"key":"824_CR26","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon A, et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 2015;1:417\u201325. https:\/\/doi.org\/10.1016\/j.cels.2015.12.004.","journal-title":"Cell Syst"},{"key":"824_CR27","doi-asserted-by":"publisher","first-page":"106936","DOI":"10.1016\/j.ijsu.2022.106936","volume":"107","author":"Y Zou","year":"2022","unstructured":"Zou Y, et al. Leveraging diverse cell-death patterns to predict the prognosis and drug sensitivity of triple-negative breast cancer patients after surgery. Int J Surg. 2022;107:106936. https:\/\/doi.org\/10.1016\/j.ijsu.2022.106936.","journal-title":"Int J Surg"},{"key":"824_CR28","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1186\/s12967-022-03632-z","volume":"20","author":"C Yan","year":"2022","unstructured":"Yan C, Niu Y, Li F, Zhao W, Ma L. System analysis based on the pyroptosis-related genes identifies GSDMC as a novel therapy target for pancreatic adenocarcinoma. J Transl Med. 2022;20:455. https:\/\/doi.org\/10.1186\/s12967-022-03632-z.","journal-title":"J Transl Med"},{"key":"824_CR29","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1093\/bioinformatics\/btq170","volume":"26","author":"MD Wilkerson","year":"2010","unstructured":"Wilkerson MD, Hayes DN. ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics. 2010;26:1572\u20133. https:\/\/doi.org\/10.1093\/bioinformatics\/btq170.","journal-title":"Bioinformatics"},{"key":"824_CR30","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41467-017-02391-6","volume":"9","author":"M Schubert","year":"2018","unstructured":"Schubert M, et al. Perturbation-response genes reveal signaling footprints in cancer gene expression. Nat Commun. 2018;9:20. https:\/\/doi.org\/10.1038\/s41467-017-02391-6.","journal-title":"Nat Commun"},{"key":"824_CR31","doi-asserted-by":"publisher","unstructured":"H\u00e4nzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-Seq data. BMC Bioinformatics. 2013;14. https:\/\/doi.org\/10.1186\/1471-2105-14-7.","DOI":"10.1186\/1471-2105-14-7"},{"key":"824_CR32","doi-asserted-by":"publisher","first-page":"687975","DOI":"10.3389\/fimmu.2021.687975","volume":"12","author":"D Zeng","year":"2021","unstructured":"Zeng D, et al. Multi-Omics Immuno-Oncology Biological Research to Decode Tumor Microenvironment and Signatures. Front Immunol. 2021;12:687975. https:\/\/doi.org\/10.3389\/fimmu.2021.687975.","journal-title":"Front Immunol"},{"key":"824_CR33","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/s13059-017-1349-1","volume":"18","author":"D Aran","year":"2017","unstructured":"Aran D, Hu Z, Butte AJ. xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol. 2017;18:220. https:\/\/doi.org\/10.1186\/s13059-017-1349-1.","journal-title":"Genome Biol"},{"key":"824_CR34","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/s13059-016-1070-5","volume":"17","author":"E Becht","year":"2016","unstructured":"Becht E, et al. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol. 2016;17:218. https:\/\/doi.org\/10.1186\/s13059-016-1070-5.","journal-title":"Genome Biol"},{"key":"824_CR35","doi-asserted-by":"publisher","unstructured":"Maeser D, Gruener R, Huang R. oncoPredict: an R package for predicting in vivo or cancer patient drug response and biomarkers from cell line screening data. Brief Bioinform. 2021;22. https:\/\/doi.org\/10.1093\/bib\/bbab260.","DOI":"10.1093\/bib\/bbab260"},{"key":"824_CR36","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1126\/science.1254257","volume":"344","author":"AP Patel","year":"2014","unstructured":"Patel AP, et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science. 2014;344:1396\u2013401. https:\/\/doi.org\/10.1126\/science.1254257.","journal-title":"Science"},{"key":"824_CR37","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1158\/2159-8290.Cd-21-0316","volume":"12","author":"Y Wu","year":"2022","unstructured":"Wu Y, et al. Spatiotemporal Immune Landscape of Colorectal Cancer Liver Metastasis at Single-Cell Level. Cancer Discov. 2022;12:134\u201353. https:\/\/doi.org\/10.1158\/2159-8290.Cd-21-0316.","journal-title":"Cancer Discov"},{"key":"824_CR38","doi-asserted-by":"publisher","unstructured":"Wu R, et al. Comprehensive analysis of spatial architecture in primary liver cancer. Sci Adv. 2021;7. https:\/\/doi.org\/10.1126\/sciadv.abg3750.","DOI":"10.1126\/sciadv.abg3750"},{"key":"824_CR39","doi-asserted-by":"publisher","unstructured":"Huang F, et al. Bile acids activate cancer-associated fibroblasts and induce an immunosuppressive microenvironment in cholangiocarcinoma. Cancer Cell. 2025;43:1460\u20131475 e1410. https:\/\/doi.org\/10.1016\/j.ccell.2025.05.017.","DOI":"10.1016\/j.ccell.2025.05.017"},{"key":"824_CR40","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1186\/s12967-025-06750-6","volume":"23","author":"W Gong","year":"2025","unstructured":"Gong W, et al. CDH3 promotes the progression of lung adenocarcinoma through driving epithelial-mesenchymal transition progress. J Transl Med. 2025;23:887. https:\/\/doi.org\/10.1186\/s12967-025-06750-6.","journal-title":"J Transl Med"},{"key":"824_CR41","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s12943-015-0448-4","volume":"14","author":"AF Vieira","year":"2015","unstructured":"Vieira AF, Paredes J. P-cadherin and the journey to cancer metastasis. Mol Cancer. 2015;14:178. https:\/\/doi.org\/10.1186\/s12943-015-0448-4.","journal-title":"Mol Cancer"},{"key":"824_CR42","doi-asserted-by":"publisher","first-page":"110","DOI":"10.5115\/acb.2010.43.2.110","volume":"43","author":"S Baek","year":"2010","unstructured":"Baek S, et al. CDH3\/P-Cadherin regulates migration of HuCCT1 cholangiocarcinoma cells. Anat Cell Biol. 2010;43:110\u20137. https:\/\/doi.org\/10.5115\/acb.2010.43.2.110.","journal-title":"Anat Cell Biol"},{"key":"824_CR43","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1038\/s41556-025-01663-4","volume":"27","author":"JRW Conway","year":"2025","unstructured":"Conway JRW, et al. Dynamic regulation of integrin beta1 phosphorylation supports invasion of breast cancer cells. Nat Cell Biol. 2025;27:1021\u201334. https:\/\/doi.org\/10.1038\/s41556-025-01663-4.","journal-title":"Nat Cell Biol"},{"key":"824_CR44","doi-asserted-by":"publisher","first-page":"106","DOI":"10.17305\/bjbms.2019.4255","volume":"20","author":"X Meng","year":"2020","unstructured":"Meng X, et al. Integrin beta 4 (ITGB4) and its tyrosine-1510 phosphorylation promote pancreatic tumorigenesis and regulate the MEK1-ERK1\/2 signaling pathway. Bosn J Basic Med Sci. 2020;20:106\u201316. https:\/\/doi.org\/10.17305\/bjbms.2019.4255.","journal-title":"Bosn J Basic Med Sci"},{"key":"824_CR45","doi-asserted-by":"publisher","first-page":"5681","DOI":"10.1038\/onc.2017.177","volume":"36","author":"K Zhang","year":"2017","unstructured":"Zhang K, et al. Oncogenic K-Ras upregulates ITGA6 expression via FOSL1 to induce anoikis resistance and synergizes with alphaV-Class integrins to promote EMT. Oncogene. 2017;36:5681\u201394. https:\/\/doi.org\/10.1038\/onc.2017.177.","journal-title":"Oncogene"},{"key":"824_CR46","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.jhep.2021.03.028","volume":"75","author":"A Vallejo","year":"2021","unstructured":"Vallejo A, et al. FOSL1 promotes cholangiocarcinoma via transcriptional effectors that could be therapeutically targeted. J Hepatol. 2021;75:363\u201376. https:\/\/doi.org\/10.1016\/j.jhep.2021.03.028.","journal-title":"J Hepatol"},{"key":"824_CR47","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1002\/ijc.30854","volume":"141","author":"S Laudato","year":"2017","unstructured":"Laudato S, et al. P53-induced miR-30e-5p inhibits colorectal cancer invasion and metastasis by targeting ITGA6 and ITGB1. Int J Cancer. 2017;141:1879\u201390. https:\/\/doi.org\/10.1002\/ijc.30854.","journal-title":"Int J Cancer"},{"key":"824_CR48","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1593\/tlo.08112","volume":"1","author":"Q Sun","year":"2008","unstructured":"Sun Q, et al. Expression of GSDML Associates with Tumor Progression in Uterine Cervix Cancer. Transl Oncol. 2008;1:73\u201383. https:\/\/doi.org\/10.1593\/tlo.08112.","journal-title":"Transl Oncol"},{"key":"824_CR49","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.tcb.2022.06.006","volume":"33","author":"AI Ivanov","year":"2023","unstructured":"Ivanov AI, Rana N, Privitera G, Pizarro TT. The enigmatic roles of epithelial gasdermin B: Recent discoveries and controversies. Trends Cell Biol. 2023;33:48\u201359. https:\/\/doi.org\/10.1016\/j.tcb.2022.06.006.","journal-title":"Trends Cell Biol"},{"key":"824_CR50","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1038\/s42255-023-00879-8","volume":"5","author":"A Mukherjee","year":"2023","unstructured":"Mukherjee A, et al. Adipocytes reprogram cancer cell metabolism by diverting glucose towards glycerol-3-phosphate thereby promoting metastasis. Nat Metab. 2023;5:1563\u201377. https:\/\/doi.org\/10.1038\/s42255-023-00879-8.","journal-title":"Nat Metab"},{"key":"824_CR51","doi-asserted-by":"publisher","first-page":"7498","DOI":"10.7150\/jca.64833","volume":"12","author":"X Yu","year":"2021","unstructured":"Yu X, Mi S, Ye J, Lou G. Aberrant lipid metabolism in cancer cells and tumor microenvironment: the player rather than bystander in cancer progression and metastasis. J Cancer. 2021;12:7498\u2013506. https:\/\/doi.org\/10.7150\/jca.64833.","journal-title":"J Cancer"},{"key":"824_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.jare.2025.04.040","author":"T Zhou","year":"2025","unstructured":"Zhou T, et al. NRXN3 regulates pyroptosis in intrahepatic cholangiocarcinoma via mediating the phospho-dependent ubiquitination and degradation of caspase-3. J Adv Res. 2025. https:\/\/doi.org\/10.1016\/j.jare.2025.04.040.","journal-title":"J Adv Res"},{"key":"824_CR53","doi-asserted-by":"publisher","unstructured":"Yang W, Hu X, Li X. Unveiling the role of gasdermin B in cancer and inflammatory disease: from molecular mechanisms to therapeutic strategies. Peerj. 2025;13. https:\/\/doi.org\/10.7717\/peerj.19392.","DOI":"10.7717\/peerj.19392"},{"key":"824_CR54","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.31083\/j.ceog4806218","volume":"48","author":"N Zhong","year":"2021","unstructured":"Zhong N, et al. Effect of GSDMB polymorphism on sensitivity to chemoradiation therapy for cervical cancer. Clin Exp Obstet Gynecol. 2021;48:1374\u201380. https:\/\/doi.org\/10.31083\/j.ceog4806218.","journal-title":"Clin Exp Obstet Gynecol"},{"key":"824_CR55","doi-asserted-by":"publisher","first-page":"3033","DOI":"10.2147\/cmar.S246948","volume":"12","author":"L Li","year":"2020","unstructured":"Li L, Li Y, Bai Y. Role of GSDMB in Pyroptosis and Cancer. Cancer Manage Res. 2020;12:3033\u201343. https:\/\/doi.org\/10.2147\/cmar.S246948.","journal-title":"Cancer Manage Res"},{"key":"824_CR56","doi-asserted-by":"publisher","DOI":"10.1186\/s12903-026-07781-1","author":"Z Cui","year":"2026","unstructured":"Cui Z, Gao Y, Yang K, Dong Z. Expression profile of GSDMB in oral squamous cell carcinoma and its impact on tumor immune microenvironment and prognosis. BMC Oral Health. 2026. https:\/\/doi.org\/10.1186\/s12903-026-07781-1.","journal-title":"BMC Oral Health"}],"container-title":["Biology Direct"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13062-026-00824-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13062-026-00824-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13062-026-00824-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:04:29Z","timestamp":1782864269000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13062-026-00824-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,7]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["824"],"URL":"https:\/\/doi.org\/10.1186\/s13062-026-00824-1","relation":{},"ISSN":["1745-6150"],"issn-type":[{"value":"1745-6150","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,7]]},"assertion":[{"value":"11 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"116"}}